← All trials
NCT05600426
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Dec 31, 2029
- Completion date
- Dec 31, 2029
- First posted
- Oct 31, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 234
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Center for International Blood and Marrow Transplant ResearchCollaborator
- Medical College of WisconsinOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Institutes of Health (NIH)Collaborator
- University of UtahOverall official - principal investigator
- Harvard UniversitySponsor investigator
- Medical College of WisconsinOfficial
- University of UtahOfficial
- Harvard UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.